Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody approved for Hodgkin's lymphoma (HL) in the pediatric population, induces sensory neuropathy. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.